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AbstrACt
Introduction Emergency department (ED)-initiated 
palliative care has been shown to improve patient-
centred outcomes in older adults with serious, life-limiting 
illnesses. However, the optimal modality for providing such 
interventions is unknown. This study aims to compare 
nurse-led telephonic case management to specialty 
outpatient palliative care for older adults with serious, 
life-limiting illness on: (1) quality of life in patients; (2) 
healthcare utilisation; (3) loneliness and symptom burden 
and (4) caregiver strain, caregiver quality of life and 
bereavement.
Methods and analysis This is a protocol for a pragmatic, 
multicentre, parallel, two-arm randomised controlled 
trial in ED patients comparing two established models of 
palliative care: nurse-led telephonic case management 
and specialty, outpatient palliative care. We will enrol 
1350 patients aged 50+ years and 675 of their caregivers 
across nine EDs. Eligible patients: (1) have advanced 
cancer (metastatic solid tumour) or end-stage organ failure 
(New York Heart Association class III or IV heart failure, 
end-stage renal disease with glomerular filtration rate 
<15 mL/min/m2, or global initiative for chronic obstructive 
lung disease stage III, IV or oxygen-dependent chronic 
obstructive pulmonary disease); (2) speak English; (3) 
are scheduled for ED discharge or observation status; 
(4) reside locally; (5) have a working telephone and (6) 
are insured. Patients will be excluded if they: (1) have 
dementia; (2) have received hospice care or two or more 
palliative care visits in the last 6 months or (3) reside 
in a long-term care facility. We will use patient-level 
block randomisation, stratified by ED site and disease. 
Effectiveness will be compared by measuring the impact of 
each intervention on the specified outcomes. The primary 
outcome will measure change in patient quality of life.
Ethics and dissemination Institutional Review Board 
approval was obtained at all study sites. Trial results will 
be submitted for publication in a peer-reviewed journal.
trial registration number NCT03325985; Pre-results.
IntroduCtIon   
rationale
According to the World Health Organization, 
palliative care is ‘an approach that improves 
the quality of life of patients and their fami-
lies facing the problems associated with 
life-threatening illness, through the preven-
tion and relief of suffering by means of early 
identification and impeccable assessment 
and treatment of pain and other problems, 
physical, psychosocial, and spiritual.’ Palli-
ative care can include hospice care, but is 
distinct from hospice in that it may be deliv-
ered throughout the time course of serious, 
life-limiting illness alongside life-prolonging, 
disease-model treatment.1 
Multiple studies have shown that palliative 
care services improve patients’ symptoms 
strengths and limitations of this study
 ► This study will be a large, randomised controlled trial 
comparing the efficacy of two palliative care models; 
it will provide evidence on which to base emergency 
department-initiated palliative care interventions.
 ► Subjects are recruited from geographically and con-
textually diverse settings across public hospitals, 
academic medical centres and community hospital 
affiliates nationwide.
 ► To ensure a pragmatic, patient-oriented interven-
tion, we incorporated feedback from patient and 
organisational stakeholders, as well as our clinical 
and research collaborators.
 ► The lack of blinding of patients and clinicians deliv-
ering the interventions is  an inherent limitation of 
the study design.
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and the quality of end-of-life care across a broad range 
of illnesses. Patients receiving palliative care services are 
often able to remain cared for and supported at home, 
leading to greater patient and family satisfaction and less 
prolonged grief and post-traumatic stress disorder among 
bereaved family members.2–7 Palliative care also lowers 
costs by reducing unnecessary hospitalisations, diagnostic 
and treatment interventions, and avoidable intensive and 
emergency department (ED) care.8–12 Randomised trials 
with palliative care interventions have demonstrated: (1) 
better quality of life and mood in patients with poor-prog-
nosis cancer who received palliative care in addition to 
standard care and (2) improved symptom management 
and patient satisfaction.9 13 Patients with late-stage chronic 
obstructive pulmonary disease (COPD) and heart failure 
who were randomly assigned to in-home palliative care, 
as compared with usual care, reported greater satisfaction 
with care and were more likely to die at home.14
The ED serves as the healthcare safety net for the most 
vulnerable, including older adults, non-Hispanic blacks, 
the poor and those with Medicaid coverage.15 Notably, 
half of older Americans visit the ED in the last month of 
life, and patients with serious illness frequently visit the 
ED, making the ED a key decision point where providers 
establish the subsequent care trajectory.16–18 Palliative 
care interventions in the ED can both capture high-risk 
patients at a time of crisis and dramatically improve 
patient-centred outcomes.19 20
Case management palliative care programmes have 
been used in older adults with multiple chronic condi-
tions and have demonstrated reductions in end of life 
healthcare utilisation and increased hospice utilisa-
tion.21–23 Many of these programmes have used nurse-led 
telephonic contact, which is less expensive and more 
accessible to seriously ill patients than outpatient palli-
ative care encounters. However, there is little to no 
research comparing the effectiveness of the telephonic 
case management model to the more costly model of 
specialty, outpatient palliative care.
Therefore, this is a protocol for a large, multicentre, 
parallel, two-arm randomised controlled trial in ED 
patients comparing two established models of pallia-
tive care: nurse-led telephonic case management and 
specialty, outpatient palliative care. The current evidence 
base has critical gaps, notably failing to achieve statistical 
power in order to ‘report conclusive results’, ‘account for 
clustering’, ‘quantify the effects’ of palliative care and 
‘address the generalisability of insights across settings’.24 25 
We address these evidence gaps in our trial by evaluating 
palliative care in a variety of ED settings, using validated 
tools to quantify changes in our outcomes of interest, and 
performing rigorous power calculations based on our 
prior randomised controlled trial of palliative care in the 
ED.
objectives
The aims of this study are to compare nurse-led telephonic 
case management to facilitated, outpatient specialty 
palliative care for older adults with serious, life-limiting 
illness on: (1) quality of life in patients, as measured by 
the Functional Assessment of Cancer Therapy-General 
(FACT-G)26 from enrolment to 6 months; (2) healthcare 
utilisation (eg, ED revisits, hospital admissions, hospice 
use)27–30 at 12 months; (3) loneliness, as measured by the 
Three-Item Loneliness Scale31 32 and symptom burden, 
as measured by Edmonton Symptom Assessment Scale 
Revised (ESAS-r)33 from enrolment to 6 months and (4) 
caregiver strain, as measured by the 12-item Zarit Burden 
Interview (ZBI-12),34 caregiver quality of life, as measured 
by the 10-item Patient-Reported Outcome Measurement 
Information System (PROMIS-10)35 and bereavement, 
as measured by the Texas Revised Inventory of Grief 
(TRIG)36 3 months after patient death.
MEthods And AnAlysIs
trial design
This is a pragmatic, two-arm, multisite randomised 
controlled trial of 1350 older adults (50+ years) with 
either poor-prognosis cancer or end-stage organ failure 
who will be recruited during an ED visit, along with 
675 of their informal caregivers, to compare nurse-led 
telephonic case management to facilitated, outpatient 
specialty palliative care. Recruitment began in April 2018 
and will continue through July 2021. All follow-up data 
collection is expected to be completed by August 2022. 
Randomisation will be at the patient level and will be strat-
ified by ED site and disease (advanced cancer vs end-stage 
organ failure) to ensure a balance of patients randomised 
to each intervention at each site. We will use block rando-
misation with random block sizes of two, four and six at 
a ratio of 1:1 assignment to each group. A biostatistician 
will randomly preassign the expected number of study 
subjects to either intervention group at each site (150 
patients at each of nine sites for a total of 1350 patients).
setting
This trial will be conducted in the EDs of nine diverse 
sites, including large public hospitals, academic medical 
centres and smaller community hospitals in different 
regions across the country (see table 1).
Prior to the start of patient recruitment, the principal 
investigator (PI) at each site notified all primary care 
providers and haematologists/oncologists in the health 
system via email of the study parameters in order to 
allow physicians to opt-out of routine participation by 
their patients. The site PI assumed that any primary care 
providers or haematologists/oncologists who did not opt 
out of participation were willing to have their eligible 
patients enrol.
Eligibility criteria
Inclusion criteria
Patients eligible for participation are English-speaking 
adults aged 50+ years with a serious, life-limiting condi-
tion. Qualifying conditions include advanced cancer 
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(defined as a solid metastatic tumour meeting advanced 
cancer criteria; see online supplementary 1) and poor 
prognosis, end-stage organ failure (defined as New 
York Heart Association class III and IV heart failure,37 38 
end-stage renal disease defined as glomerular filtration 
rate <15 mL/min/m2 or global initiative for chronic 
obstructive lung disease stage III and IV or oxygen-de-
pendent COPD defined as forced expiratory volume in 
1 s <50% predicted or the modified Medical Research 
Council dyspnoea scale).39 Patients must be scheduled 
for ED discharge or observation status. Patients who are 
placed in observation overnight will still be eligible to 
participate the following morning. For sites with no obser-
vation unit, patients with an expected admission of two 
nights or less will be eligible. Patients must have health 
insurance, reside within the geographical area and have a 
working telephone. These inclusion criteria are designed 
to ensure that patient participants are able to engage in 
the intervention and follow-up procedures.
Exclusion criteria
We will exclude those patients with dementia identified 
in the electronic health records (EHRs), received hospice 
services or two or more palliative care visits in the last 6 
months, or reside in a skilled nursing or assisted living 
facility or chronic care hospital. These exclusion criteria 
are in place to ensure effective engagement with the inter-
vention and follow-up protocols. No specific genders or 
racial or ethnic origins will be excluded from this study. 
Children, pregnant patients and prisoners will not be 
recruited.
Caregiver criteria
English-speaking primary caregivers aged 18+ years who 
accompany eligible, enrolled patients will be eligible to 
participate. The caregiver must fulfil one of the following 
categories: (1) immediate or extended family member 
or (2) close friend who lives with the eligible patient 
full time. Caregivers must possess a working telephone 
and cannot be currently compensated for providing care 
to a patient if not a family member. The caregiver sample 
will exclude individuals <18 years old because the unique 
stresses a child caregiver experiences are outside of the 
scope of this study. No specific genders and racial and 
ethnic origins will be excluded from this study.
Table 1 ED characteristics and eligible adult patients with serious illness, by year
Site Location
Inpatient 
beds Admissions ED visits
Eligible*,
no (% of ED 
visits)
Discharged or 
Observed†, no 
(% of eligible)
New York University 
(NYU) School of Medicine 
  Perelman ED/Tisch Hospital New York City, New 
York, USA 
718 38 045 60 096 9014 (15) 2704 (30) 
  Bellevue Hospital Center  ED New York City, New 
York, USA 
827 29 793 122 389 11 015 (9) 2203 (20) 
  NYU Hospital Brooklyn ED Brooklyn, New York, 
USA 
450 24 748 68 060 8167 (12) 2041 (25) 
Brigham and Women’s/Dana 
Farber Cancer Institute 
  Brigham and Women’s ED Boston, 
Massachusetts, USA 757 19 091 62 000 9300 (15) 2511 (27)
Beaumont 
  Royal Oak Royal Oak, 
Michigan, USA
1070 58 539 120 000 25 666 (21) 3853 (15) 
  Troy Troy, Michigan, USA 520 33 759 79 000 17 434 (22) 2151 (12)
Ohio State University 
  Wexner Medical Center Columbus, Ohio, USA 962 45 927 120 156 17 801 (15) 8393 (47)
University of Florida (UF) 
  UF Shands Gainesville, 
Florida, USA
973 41 669 75 537 15 561 (21) 5176 (33)
Yale University 
  Yale New Haven New Haven, 
Connecticut, USA
1576 54 412 141 422 11 828 (8) 4408 (37)
*ED-admissions by patients with ICD-9 or ICD-10 codes consistent with advanced cancer or end-stage organ failure.
†Patients who met criteria based on ICD-9 and ICD-10 codes who were discharged home from the ED or the observation unit.
ED, emergency department.
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recruitment
Research assistants (RAs) will check the ED and obser-
vation unit electronic track boards at each site at least 
two to three times a day to identify patients with previ-
ously defined qualifying conditions. The RAs will review 
patients’ EHRs to confirm inclusion criteria are met. This 
recruitment method will ensure the RAs only approach 
patients who are potentially eligible for the study.
RAs will then approach patients and conduct face-to-
face interviews to confirm that patients meet all eligibility 
criteria. Once eligibility is established, RAs will discuss 
with patients the purpose, requirements and timeline 
of the study. For patients interested in enrolling for the 
study, RAs will then review the consent form with partic-
ipants and obtain signed, informed consent (see online 
supplementaries 2 and 3).
After informed consent is signed, a baseline face-to-face 
survey will be conducted at bedside to document partic-
ipants’ demographics and quality of life, loneliness and 
symptom burden.
After patient enrolment, RAs will assess accompanying 
caregivers and discuss their participation in the study. With 
each caregiver agreeing to participate, RAs will review the 
caregiver consent form, obtain signed, informed consent 
and conduct a baseline face-to-face survey.
Each patient and caregiver will be offered a US$40 
gift card to participate with a repeated compensation 
of a US$20 gift card for completing each subsequent 
follow-up survey over the phone. Patients randomised to 
the outpatient arm will receive a US$25 gift card for each 
appointment attended during study enrolment.
randomisation and blinding
After a patient has enrolled in the study and completed 
the baseline interview, an automated notification will 
be sent to the project manager, who will initiate patient 
randomisation based on the previously generated allo-
cation sequence. Depending on patient assignment, the 
project manager will relay the patient’s contact informa-
tion to the telephonic nurses or outpatient palliative care 
clinic so that they can initiate the appropriate interven-
tion. A list linking the patient name and group assign-
ment will only be accessible to the project manager and 
data analyst; RAs and other staff involved in recruitment, 
follow-up and analysis will remain blinded to patient 
assignment. It is not feasible to blind study subjects or 
care providers to patient assignment. The unit of anal-
ysis will be the patient, and a blinded outcome assessment 
will occur for all patient and caregiver participants at 12 
weeks, 6 months and 12 months. Please refer to figure 1 
for the study overview diagram.
treatment arms
Both treatment arms will include standardised assess-
ments and referral for patients randomised to either 
group, as well as criteria for the timing and frequency 
of follow-up visits and phone calls. All care will 
address ongoing concerns within the eight domains of 
palliative care1: (1) structure and processes of care (eg, 
goals of care); (2) physical aspects of care (eg, pain); 
(3) psychological aspects of care (eg, depression); (4) 
social aspects of care (eg, caregiver burden); (5) spiri-
tual aspects of care (eg, hopes and fears); (6) cultural 
aspects of care (eg, ritual); (7) care of the imminently 
dying (eg, prognosis) and (8) ethical and legal aspects 
of care (eg, advance directives). 
Nurse-led telephonic case management arm
Nurse-led telephonic case management will be conducted 
at a central site located at the primary site, New York 
University School of Medicine (NYUSoM). A registered 
nurse with a Certified Hospice and Palliative Nurse certi-
fication will interact with patients via telephone and 
deliver quality care according to the eight domains of 
palliative care as described above. The nurse will contact 
the patient once a week, or more frequently according to 
patient needs, for a duration of 6 months.
Facilitated, outpatient care arm
Facilitated, outpatient specialty palliative care visits will 
take place face to face in the outpatient facilities at each 
participating clinical site. A physician or nurse practi-
tioner board eligible or board certified in hospice and 
palliative medicine will also deliver care according to the 
eight domains of palliative care as outlined above. The 
patient will be scheduled to meet with the outpatient 
team once a month for a duration of 6 months.
Follow-up assessments
While receiving either intervention, all enrolled patients 
and caregivers will participate in follow-up assessments 
using the same questionnaires that were completed at 
baseline (FACT-G, Three-Item Loneliness Scale, ESAS-r, 
ZBI-12, PROMIS-10). RAs will complete follow-up assess-
ments over the phone. For both caregivers and patients, 
follow-ups will take place 12 weeks, 6 months and 12 
months after enrolment.
If patient death occurs during the course of the study, 
the caregiver will be asked additional questions about 
bereavement using the TRIG survey. This bereavement 
instrument is completed 3 months after patient death.
outcome measures
Outcomes were specified ahead of time. Dependent and 
independent variables are collected by blinded RAs via 
face-to-face bedside interview or EHR at baseline prior to 
randomisation and over the phone at 12 weeks, 6 months 
and 12 months. Healthcare utilisation data, including ED 
revisits, inpatient days and hospice use, will be abstracted 
from the EHR and administrative data at 12 months. 
Independent and dependent variables are listed in online 
supplementaries 4 and 5, respectively.
The primary outcome is change in patient quality 
of life from enrolment to 6 months, as measured by 
the FACT-G. The FACT-G is a 27-item questionnaire 
assessing quality of life domains in physical, social, 
emotional and functional well-being.26 While it has been 
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used extensively in oncology, it is validated and used as 
an assessment of chronic illness therapy in many other 
serious illnesses.40
Secondary outcomes in patients include healthcare util-
isation (ED visits, hospital admissions and hospice use) 
from enrolment to 12 months; loneliness, as measured by 
change in the Three-Item Loneliness Scale from enrol-
ment to 6 months; symptom burden, as measured by 
change in the ESAS-r from enrolment to 6 months and 
quality of life, as measured by the FACT-G, at 12 weeks 
and 12 months. Secondary outcomes in caregivers include 
caregiver physical and psychosocial distress, as measured 
by change in the ZBI-12 from enrolment to 6 months; 
caregiver quality of life, as measured by change in the 
PROMIS-10 from enrolment to 6 months and bereave-
ment as measured by the TRIG at 3 months after patient 
death.
Adverse events
Numerous important medical events, such as hospi-
talisation and death, are expected due to the stage of 
patients’ illnesses and will be unrelated to the study. We 
do not expect any study-related serious adverse events.
data collection and management
Data collection is performed by trained RAs at each 
study site, and data entry into a Research Electronic 
Data Capture (REDCap) database is completed in a stan-
dardised fashion on tablets and computers. REDCap is a 
secure, web-based application designed to support data 
capture for research studies.41
statistical analysis
The primary effect of interest is the change in quality 
of life of patients with serious, life-limiting illness from 
Figure 1 Study overview diagram. ED, emergency department.
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baseline to 6 months as measured by the FACT-G. The 
effect size parameter will be estimated by comparing 
patients who receive telephonic palliative care with 
those who receive outpatient palliative care. Randomi-
sation will be done at the site level and stratified by 
primary diagnosis. This ensures that each of the nine 
sites will have patients in both intervention arms, and 
patients with cancer will be randomised separately 
from those who have an organ failure diagnosis. To 
account for nesting in the data structure (patients 
nested in hospitals), we will use mixed effect multilevel 
linear model to estimate effect sizes. We anticipate 
two sources of variation. First, there will be regional 
(site) variation in the outcomes independent of the 
intervention; although the telephonic arm is centrally 
delivered, there may still be clustering at the site level. 
Second, there will be variation in how specialty, palli-
ative care outpatient clinics deliver the clinic inter-
vention arm, which will add an additional source of 
variation for this arm alone. We will adjust for cancer 
status to account for differences in outcomes for the 
patients with cancer and non-cancer in the study. If 
we conclude there is enough evidence that suggests 
there is an intervention effect (based on a t-test using 
α=0.05), we will use a second model to assess whether 
the treatment effect differs for patients with cancer 
and organ failure.
We will analyse the secondary outcomes using similar 
multilevel models. In one set of analyses, we will be inves-
tigating whether the intervention affects healthcare 
utilisation following the initial ED visit. These outcomes—
subsequent ED visits (counts), inpatient days (counts) 
and hospice use (binary)—will require generalised linear 
mixed effect models; for the count models we will consider 
Poisson or negative binomial distributions, and for the 
binary outcome we will use logistic regression. In a second 
set of analyses, we will be measuring the intervention 
effects on additional quality of life measures—loneliness, 
symptom burden, caregiver strain, caregiver quality of life 
and bereavement—which are all continuous measures. For 
these analyses, we will use linear mixed effect models.
sample size calculation
Simulation methods were used to estimate power 
based on the primary outcome, a change in quality of 
life from enrolment to 6 months as measured by the 
FACT-G. In the simulations, we incorporated the two 
sources of variability at the site level, as described in 
the statistical plan. We further assumed a drop-out rate 
of 15% due to death or drop-out, as we will recruit 
patients earlier in the course of their advanced illness 
when they are still well enough to be discharged 
home. With an effective sample size of 287 subjects in 
each comparison arm, we will achieve 100% power to 
detect an effect of nurse-led telephonic care given an 
overall effect of 4 points on the FACT-G, a clinically 
meaningful difference in quality of life. Moreover, this 
sample size will provide about 80% power to detect a 
difference in effect sizes between the groups given that 
the true difference is only 2 points.
Patient and public involvement
A study advisory committee was assembled of (1) 
patients with serious, life-limiting illness and their 
caregivers; (2) the chief medical executive of a large 
Medicare Advantage Plan; (3) community faculty from 
Charles R. Drew University of Medicine and Science, 
Division of Community Engagement; (4) patient 
advocates from stakeholder organisations (eg, Amer-
ican Heart Association, American Cancer Society, 
Equity Healthcare, Cambia Health); (5) representa-
tives from Emergency Medicine and Palliative Care 
organisations (eg, Society for Academic Emergency 
Medicine, Hospice and Palliative Nurses Associa-
tion, Emergency Nurses Association) and (6) other 
content experts. These key stakeholders, who have a 
history of cofunding, copublication and collaboration, 
are involved in all stages of the research, including 
the development of appropriate comparators and 
outcomes of interest, the conduct and oversight of the 
study, and analysis and dissemination of the results.
Monitoring
The PI, in cooperation with the coinvestigators and the 
NYUSoM Institutional Review Board (IRB), will monitor 
the safety of the proposed project. We have created a 
data safety and monitoring plan and established formal 
monitoring procedures at each site to closely monitor 
participant safety, data quality and study progress. A data 
monitoring committee is not needed since the study is 
minimal risk.
Monitoring for protocol adherence will be performed 
monthly to ensure early identification of poor perfor-
mance at individual sites and in the trial overall. Specific 
parameters to be monitored will include randomisation 
of ineligible subjects and treatment allocation errors. Our 
study protocol will continue to be informed by our patient 
and organisational stakeholders throughout its initiation.
EthICs And dIssEMInAtIon
safety considerations
IRB approval was first obtained at NYUSoM, followed by 
approval from the other study sites (see online supple-
mentary 6). To minimise research-associated risk and 
protect the confidentiality of participant data, all inves-
tigators and staff involved in this project have completed 
extensive courses and passed certifying examinations on 
the protection of human subjects in research through 
Collaborative Institutional Training Initiative training 
and Health Insurance Portability and Accountability Act 
certification.
dissemination plan
Patient and organisational stakeholders will significantly 
contribute to the translation of the research findings into 
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lay language. Additionally, our group has long-standing 
relationships with large, disease-based not-for-profit 
organisations and will work closely with these stakeholders 
to develop and activate their communications infrastruc-
ture to disseminate our results through social media, 
community-based outreach and local academic partners. 
Furthermore, the results of this study will be submitted 
to  ClinicalTrials. gov, and peer-review publications will be 
coauthored by the research team.
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